selenium has been researched along with exenatide in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barakat, GM; Bikhazi, AB; Moustafa, ME | 1 |
| Han, L; Hong, A; Li, YW; Ma, M; Ma, Y; Wan, DC; Wang, DH; Xiao, X; Zhao, SJ | 1 |
| Barakat, G; Bikhazi, A; Hodroj, MH; Khalifeh, I; Moustafa, ME; Rizk, S | 1 |
3 other study(ies) available for selenium and exenatide
| Article | Year |
|---|---|
Effects of selenium and exendin-4 on glucagon-like peptide-1 receptor, IRS-1, and Raf-1 in the liver of diabetic rats.
Topics: Animals; Blood Glucose; Blotting, Western; Diabetes Mellitus, Experimental; Exenatide; Glucagon-Like Peptide-1 Receptor; Hypoglycemic Agents; Insulin; Insulin Receptor Substrate Proteins; Liver; Male; MAP Kinase Kinase Kinases; Peptides; Proto-Oncogene Proteins c-raf; Rats; Rats, Sprague-Dawley; Receptors, Glucagon; RNA, Messenger; Selenium; Sodium Selenite; Streptozocin; Time Factors; Venoms | 2012 |
A novel selective VPAC2 agonist peptide-conjugated chitosan modified selenium nanoparticles with enhanced anti-type 2 diabetes synergy effects.
Topics: Animals; Blood Glucose; Cell Proliferation; Chitosan; Diabetes Mellitus, Type 2; Drug Liberation; Exenatide; Fasting; Glucose; Half-Life; Hydrogen Peroxide; Insulin; Insulin Resistance; Male; Mice; Nanoparticles; Peptides; Reactive Oxygen Species; Receptor, Insulin; Receptors, Vasoactive Intestinal Peptide, Type II; RNA, Messenger; Selenium; Venoms | 2017 |
Effects of exendin-4 and selenium on the expression of GLP-1R, IRS-1, and preproinsulin in the pancreas of diabetic rats.
Topics: Animals; Diabetes Mellitus, Experimental; Exenatide; Glucagon-Like Peptide-1 Receptor; Hypoglycemic Agents; Insulin; Insulin Receptor Substrate Proteins; Male; Pancreas; Peptides; Protein Precursors; Rats, Sprague-Dawley; Selenium; Venoms | 2016 |